We are the Artful Dodgers of the globalised world, experts at ducking and diving - but even the Dodger gets caught in the end ...
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...
Investor's Business Daily on MSN4d
As The Biotech Sector Remains Strong, Vertex Stock Trades Near Buy PointBiotech stocks are among the few industry groups producing breakouts and buyable stocks in an uncertain market. Vertex stock ...
Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...
Zacks Investment Research on MSN5d
Vertex Pharmaceuticals (VRTX) Rises But Trails Market: What Investors Should KnowVertex Pharmaceuticals (VRTX) closed the latest trading day at $512.52, indicating a +0.06% change from the previous session's end. The stock's change was less than the S&P 500's daily gain of 1.08%.
Intel hasn't been very good with processors lately. Perhaps they are focusing on creating video cards and competing with ...
After hours: March 21 at 7:13:50 PM EDT Loading Chart for VRTX ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback